MCID: VTR013
MIFTS: 50

Vitreoretinopathy, Neovascular Inflammatory

Categories: Genetic diseases, Eye diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

MalaCards integrated aliases for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 54 24 71 29 13
Proliferative Vitreoretinopathy 12 24 71 14 69
Adniv 56 71
Vrni 24 71
Pvr 24 71
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 56
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 71
Vitreoretinopathy, Proliferative 42
Proliferative Vitreo-Retinopathy 69
Vitreoretinopathy Proliferative 52
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

56
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

OMIM:

54
Inheritance:
autosomal dominant (11q13)


HPO:

32
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare eye diseases


External Ids:

OMIM 54 193235
Disease Ontology 12 DOID:9719
MeSH 42 D018630
SNOMED-CT 64 193364004 232016005
Orphanet 56 ORPHA329211
ICD10 via Orphanet 34 H35.2
MedGen 40 C1860404
UMLS 69 C0242852

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 71 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to poliomyelitis and paralytic poliomyelitis, and has symptoms including retinal detachment, blindness and uveitis. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Triamcinolone and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

OMIM : 54
Autosomal dominant neovascular inflammatory vitreoretinopathy is a blinding disorder that shares some clinical features with retinitis pigmentosa (see 268000), uveitis, and proliferative diabetic retinopathy (see 603933). Features include prominent ocular inflammation; vascular dropout, large spots of hyperpigmentation, and neovascularization of the peripheral and posterior retina; vitreous hemorrhage; and retinal detachment (summary by Sheffield et al., 1992). (193235)

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Related Disease Score Top Affiliating Genes
1 poliomyelitis 11.0
2 paralytic poliomyelitis 10.9
3 cardiac tamponade 10.8
4 pericardial effusion 10.8
5 urethral diverticulum 10.8
6 enterocele 10.8
7 prolapse of female genital organ 10.8
8 cleft lip/palate-ectodermal dysplasia syndrome 10.8
9 andersen syndrome 10.8
10 basilar artery insufficiency 10.8
11 ovarian cystic teratoma 10.8
12 congenital bile acid synthesis defect 10.8
13 pericardium disease 10.8
14 heart conduction disease 10.8
15 retinitis 10.8
16 retinal detachment 10.7
17 hyperinsulinism 10.6 GFAP TGFB2
18 anhidrosis 10.5 CTGF TGFB1
19 scrotal carcinoma 10.4 FGF2 TGFB1
20 colorectal adenoma 10.4 FGF2 HGF
21 acromicric dysplasia 10.4 CTGF TGFB1 TGFB2
22 platelet glycoprotein iv deficiency 10.4 HGF MET
23 osteofibrous dysplasia 10.3 HGF MET
24 sarcomatoid squamous cell skin carcinoma 10.3 HGF MET
25 connective tissue cancer 10.3 FGF2 GFAP TGFB1
26 adult medulloblastoma 10.3 HGF MET
27 aggressive systemic mastocytosis 10.3 GFAP MET
28 esophageal candidiasis 10.2 CAPN5 CCL2 TGFB2
29 endotheliitis 10.2
30 pulmonary valve insufficiency 10.2 CCL2 CTGF TGFB1
31 malignant granular cell skin tumor 10.1 ADM CCL2 TGFB2
32 hypertrichosis of eyelid 10.1 CCL2 CTGF TGFB1
33 cranial nerve malignant neoplasm 10.1 CCL2 FGF2 TGFB1
34 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 CCL2 CTGF TGFB1
35 duane anomaly mental retardation 10.1 HGF MET
36 middle lobe syndrome 10.1 CCL2 CTGF TGFB1
37 calcinosis 10.1 CCL2 CTGF TGFB1
38 cholera 10.0 CTGF TGFB1 TIMP1
39 nephrotic syndrome, idiopathic, steroid-resistant 10.0 CTGF TGFB1 TIMP1
40 cataract 10.0
41 salt and pepper syndrome 10.0 CTGF TGFB1 TIMP1
42 myelophthisic anemia 10.0 ADM CCL2 HGF
43 nervous system cancer 10.0 CTGF TGFB1 TIMP1
44 ulnar neuropathy 10.0 GFAP TIMP1
45 strawberry gallbladder 9.9 TGFB1 TGFB2
46 intravascular angioleiomyoma 9.9 FGF2 SPARC
47 choroiditis 9.9
48 perrault syndrome 9.9 CCL2 CTGF HGF TGFB1
49 ichthyosis lamellar 1 9.8 GFAP TGFB1 TGFB2
50 purulent endophthalmitis 9.8 CTGF FGF2 GFAP TGFB2 VTN

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Symptoms via clinical synopsis from OMIM:

54

Lab:
distinct b-wave abnormality on electrooculography

Eyes:
retinal detachment
vitreous hemorrhage
neovascularization of peripheral and posterior retina
retinal vascular dropout
large hyperpigmented retinal spots
more

Clinical features from OMIM:

193235

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

32 (show all 9)
id Description HPO Frequency HPO Source Accession
1 retinal detachment 32 HP:0000541
2 blindness 32 HP:0000618
3 uveitis 32 HP:0000554
4 abnormal electroretinogram 32 HP:0000512
5 vitreous hemorrhage 32 HP:0007902
6 large hyperpigmented retinal spots 32 HP:0007658
7 vitreoretinopathy 32 HP:0007773
8 posterior retinal neovascularization 32 HP:0007778
9 peripheral retinal neovascularization 32 HP:0030667

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ADM CTGF FGF2 GFAP HGF MET
2 homeostasis/metabolism MP:0005376 10.06 FGF1 FGF2 GFAP MET SPARC TGFB1
3 hematopoietic system MP:0005397 10.02 ADM FGF1 FGF2 HGF SPARC TGFB1
4 immune system MP:0005387 9.91 MET SPARC TGFB1 TGFB2 TIMP1 ADM
5 mortality/aging MP:0010768 9.85 ADM CAPN5 CTGF FGF2 GFAP HGF
6 respiratory system MP:0005388 9.43 CTGF MET TGFB1 TGFB2 TIMP1 ADM
7 vision/eye MP:0005391 9.17 CTGF FGF2 GFAP MET SPARC TGFB1

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
3
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
4 Anti-Inflammatory Agents Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 3
6 Hormone Antagonists Phase 4,Phase 3
7 Hormones Phase 4,Phase 3
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
9 Peripheral Nervous System Agents Phase 4,Phase 3
10 triamcinolone acetonide Phase 4,Phase 3
11 Triamcinolone diacetate Phase 4,Phase 3
12 Triamcinolone hexacetonide Phase 4,Phase 3
13 Dermatologic Agents Phase 4
14 Anesthetics Phase 4
15 Anesthetics, Local Phase 4
16 Central Nervous System Depressants Phase 4
17 Immunosuppressive Agents Phase 4,Phase 3
18
Colchicine Approved Phase 3 64-86-8 6167 2833
19
Dalteparin Approved Phase 3 9005-49-6
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Fluorouracil Approved Phase 3 51-21-8 3385
22
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
23
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
24 Antimitotic Agents Phase 3
25 Antirheumatic Agents Phase 3
26 Anticoagulants Phase 3
27 Antiemetics Phase 3
28 Antineoplastic Agents, Hormonal Phase 3
29 Autonomic Agents Phase 3
30 BB 1101 Phase 3
31 calcium heparin Phase 3
32 Calcium, Dietary Phase 3
33 Dexamethasone acetate Phase 3 1177-87-3
34 Fibrinolytic Agents Phase 3
35 Gastrointestinal Agents Phase 3
36 Heparin, Low-Molecular-Weight Phase 3
37 HIV Protease Inhibitors Phase 3
38
protease inhibitors Phase 3
39 Antimetabolites Phase 3
40 Antimetabolites, Antineoplastic Phase 3
41 Pharmaceutical Solutions Phase 3
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43 Angiogenesis Inhibitors Phase 2
44 Angiogenesis Modulating Agents Phase 2

Interventional clinical trials:

(show all 20)

id Name Status NCT ID Phase Drugs
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
4 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3 low molecular weight heparin, 5-FU
6 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
9 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
10 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3 Triamcinolone Acetonide
12 Bevacizumab Against Recurrent Retinal Detachment Unknown status NCT02192970 Phase 2 Bevacizumab
13 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2 Decorin
14 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619
15 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
16 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293
17 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586 Bevacizumab
18 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Recruiting NCT01959568
19 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531
20 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Not yet recruiting NCT02748421

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

id Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 29 24 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

39
Eye, Retina

Publications for Vitreoretinopathy, Neovascular Inflammatory

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

71
id Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 49)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CTGF FGF1 FGF2 HGF MET TGFB1
2
Show member pathways
13.76 CAPN5 CCL2 CTGF FGF1 FGF2 GFAP
3
Show member pathways
13.64 CTGF FGF1 FGF2 HGF MET TGFB1
4
Show member pathways
13.48 CTGF FGF1 FGF2 HGF MET TGFB1
5
Show member pathways
13.48 CCL2 CTGF FGF1 FGF2 HGF MET
6
Show member pathways
13.32 CCL2 CTGF FGF1 FGF2 HGF MET
7
Show member pathways
13.29 CCL2 FGF1 FGF2 HGF MET TGFB1
8
Show member pathways
13.27 CTGF FGF1 FGF2 HGF MET TGFB1
9
Show member pathways
13.23 CTGF FGF1 FGF2 HGF MET TGFB1
10
Show member pathways
13.17 CCL2 CTGF FGF1 FGF2 HGF MET
11
Show member pathways
12.99 CTGF FGF1 FGF2 HGF MET TGFB1
12
Show member pathways
12.79 CCL2 CTGF FGF1 FGF2 HGF MET
13
Show member pathways
12.68 CAPN5 FGF2 SPARC TGFB1 TGFB2 TIMP1
14
Show member pathways
12.65 FGF1 FGF2 HGF MET
15
Show member pathways
12.64 FGF1 FGF2 HGF MET
16 12.64 FGF1 FGF2 HGF MET TGFB1 TGFB2
17 12.63 FGF1 FGF2 TGFB1 TGFB2
18 12.61 FGF1 FGF2 HGF MET VTN
19
Show member pathways
12.49 FGF1 FGF2 HGF MET TGFB1 TGFB2
20
Show member pathways
12.38 CTGF FGF1 FGF2 HGF MET TGFB1
21 12.19 FGF2 HGF MET TGFB1 TGFB2 VTN
22 12.11 CTGF FGF1 TGFB1 TGFB2
23 12.04 FGF2 HGF MET TGFB1
24 12.03 HGF TGFB1 TGFB2
25 12.02 FGF1 FGF2 MET
26 11.97 CCL2 FGF2 HGF TGFB1 TIMP1
27 11.94 CCL2 GFAP TGFB1
28 11.89 FGF2 SPARC TGFB1 TGFB2
29 11.88 SPARC TGFB1 VTN
30 11.85 CCL2 TGFB1 TGFB2
31 11.8 CCL2 TGFB1 TGFB2
32
Show member pathways
11.7 TGFB1 TGFB2 VTN
33
Show member pathways
11.66 FGF2 TGFB1 VTN
34 11.64 FGF2 TGFB1 TGFB2
35 11.61 SPARC TIMP1 VTN
36 11.61 SPARC TGFB1 TGFB2 VTN
37 11.6 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
38 11.52 FGF1 FGF2 HGF TGFB1
39 11.5 FGF2 TGFB1 TGFB2
40 11.48 FGF1 HGF MET
41 11.44 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
42 11.41 CCL2 HGF MET TGFB1 TGFB2
43 11.21 HGF MET TGFB1 TGFB2
44 11.1 CCL2 TIMP1
45 11.01 TGFB1 TGFB2
46 11 HGF MET TGFB1
47 10.97 CCL2 TIMP1
48 10.97 CCL2 CTGF FGF1 FGF2 HGF TGFB1
49 10.85 TGFB1 TGFB2

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.73 CTGF FGF1 SPARC TGFB1 TIMP1 VTN
2 extracellular space GO:0005615 9.7 ADM CCL2 CTGF FGF1 FGF2 HGF
3 extracellular matrix GO:0031012 9.67 TGFB1 TGFB2 TIMP1 VTN
4 platelet alpha granule lumen GO:0031093 9.55 HGF SPARC TGFB1 TGFB2 TIMP1
5 basement membrane GO:0005604 9.5 SPARC TIMP1 VTN
6 extracellular region GO:0005576 9.4 ADM CCL2 CTGF FGF1 FGF2 HGF

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 FGF1 HGF MET TGFB1 TGFB2
2 heart development GO:0007507 9.95 ADM SPARC TGFB1 TGFB2
3 response to hypoxia GO:0001666 9.91 ADM CCL2 TGFB1 TGFB2
4 peptidyl-tyrosine phosphorylation GO:0018108 9.9 FGF1 FGF2 HGF MET
5 angiogenesis GO:0001525 9.89 CCL2 CTGF FGF1 FGF2 TGFB2
6 activation of MAPK activity GO:0000187 9.87 FGF1 FGF2 HGF
7 lung development GO:0030324 9.87 CTGF FGF1 SPARC
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.86 CCL2 TGFB1 TGFB2
9 response to organic substance GO:0010033 9.86 ADM TGFB1 TIMP1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 HGF TGFB1 VTN
11 positive regulation of angiogenesis GO:0045766 9.85 ADM FGF1 FGF2 HGF
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 CCL2 CTGF FGF1 FGF2 TGFB1
13 fibroblast growth factor receptor signaling pathway GO:0008543 9.84 CTGF FGF1 FGF2
14 neural tube closure GO:0001843 9.84 ADM TGFB1 TGFB2
15 phosphatidylinositol-mediated signaling GO:0048015 9.84 FGF1 FGF2 HGF MET
16 response to glucocorticoid GO:0051384 9.83 ADM CCL2 SPARC
17 aging GO:0007568 9.83 ADM CCL2 CTGF TGFB1 TIMP1
18 positive regulation of MAP kinase activity GO:0043406 9.82 FGF1 FGF2 TGFB1
19 extracellular matrix organization GO:0030198 9.81 FGF2 SPARC VTN
20 phosphatidylinositol phosphorylation GO:0046854 9.81 FGF1 FGF2 HGF MET
21 inner ear development GO:0048839 9.8 SPARC TGFB1 TGFB2
22 response to peptide hormone GO:0043434 9.8 CTGF SPARC TIMP1
23 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.78 FGF1 FGF2 HGF MET
24 response to progesterone GO:0032570 9.76 CCL2 TGFB1 TGFB2
25 positive chemotaxis GO:0050918 9.75 FGF2 HGF MET
26 epithelial to mesenchymal transition GO:0001837 9.74 HGF TGFB1 TGFB2
27 MAPK cascade GO:0000165 9.73 CCL2 FGF1 FGF2 HGF MET TGFB1
28 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 FGF2 TGFB1
29 platelet degranulation GO:0002576 9.72 HGF SPARC TGFB1 TGFB2 TIMP1
30 cell-cell junction organization GO:0045216 9.71 TGFB1 TGFB2
31 negative regulation of blood vessel endothelial cell migration GO:0043537 9.71 FGF2 TGFB1
32 hyaluronan catabolic process GO:0030214 9.71 FGF2 TGFB1
33 cell activation GO:0001775 9.71 TGFB1 TIMP1
34 animal organ regeneration GO:0031100 9.71 ADM CCL2 HGF TGFB1
35 positive regulation of wound healing GO:0090303 9.7 CCL2 VTN
36 negative regulation of immune response GO:0050777 9.7 TGFB1 TGFB2
37 pathway-restricted SMAD protein phosphorylation GO:0060389 9.7 TGFB1 TGFB2
38 positive regulation of collagen biosynthetic process GO:0032967 9.7 CCL2 CTGF TGFB1
39 hepatocyte growth factor receptor signaling pathway GO:0048012 9.69 HGF MET
40 glial cell migration GO:0008347 9.68 CCL2 TGFB2
41 positive regulation of sprouting angiogenesis GO:1903672 9.68 FGF1 FGF2
42 salivary gland morphogenesis GO:0007435 9.67 TGFB1 TGFB2
43 positive regulation of cell division GO:0051781 9.67 FGF1 FGF2 TGFB1 TGFB2
44 SMAD protein import into nucleus GO:0007184 9.66 TGFB1 TGFB2
45 heart valve morphogenesis GO:0003179 9.64 TGFB1 TGFB2
46 negative regulation of macrophage cytokine production GO:0010936 9.62 TGFB1 TGFB2
47 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.61 HGF MET
48 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.56 FGF1 FGF2
49 positive regulation of cell proliferation GO:0008284 9.56 ADM CTGF FGF1 FGF2 HGF TGFB1
50 wound healing GO:0042060 9.55 FGF2 SPARC TGFB1 TGFB2 TIMP1

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.73 FGF1 FGF2 HGF MET
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.67 FGF1 FGF2 HGF MET
3 cytokine activity GO:0005125 9.65 CCL2 FGF2 TGFB1 TGFB2 TIMP1
4 integrin binding GO:0005178 9.5 CTGF FGF1 VTN
5 type II transforming growth factor beta receptor binding GO:0005114 9.46 TGFB1 TGFB2
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 FGF1 FGF2 HGF MET
7 type III transforming growth factor beta receptor binding GO:0034714 9.4 TGFB1 TGFB2
8 heparin binding GO:0008201 9.35 CCL2 CTGF FGF1 FGF2 VTN
9 growth factor activity GO:0008083 9.17 CTGF FGF1 FGF2 HGF TGFB1 TGFB2

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....